The in vitro biological activity of the HLA-DR-binding clinical IgG4 antibody 1D09C3 is a consequence of the disruption of cell aggregates and can be abrogated by Fab arm exchange.

@article{Hansen2009TheIV,
  title={The in vitro biological activity of the HLA-DR-binding clinical IgG4 antibody 1D09C3 is a consequence of the disruption of cell aggregates and can be abrogated by Fab arm exchange.},
  author={K. Hansen and Ivo R. Ruttekolk and Heike Glauner and F. Becker and R. Brock and S. Hannus},
  journal={Molecular immunology},
  year={2009},
  volume={46 16},
  pages={
          3269-77
        }
}
Antibodies of the IgG4 subclass, directed against cell surface antigens have received attention as therapeutic molecules due to their poor induction of the complement system. The MHC class II-directed IgG4 antibody 1D09C3 has been explored for the treatment of lymphomas. The mechanism-of-action is still controversial. Apoptosis induction following HLA-DR engagement has been proposed. However, the validity of these results has been questioned by the observation that antibodies may induce… Expand
A New Classification System for IgG4 Autoantibodies
Antibody-Based Therapies in Multiple Myeloma
Potential therapeutic utility of hybridized IgG4 antibodies.
Reply to Fab-arm exchange
B cell MHC class II signaling: A story of life and death.
Fluorescence cross-correlation spectroscopy (FCCS) in living cells.

References

SHOWING 1-10 OF 24 REFERENCES
...
1
2
3
...